📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
520 announcements match the current filters (relevance ≥ 5).
CARE Ratings Q3 FY26 Net Profit Jumps 29% YoY to ₹35.9 Crore
CARE Ratings Limited reported a robust year-on-year performance for the quarter ended December 31, 2025 (Q3 FY26), with consolidated revenue from operations rising 16.3% to ₹112.12 crore. Net profit attributable to owners saw a significant jump of 29.1% YoY, reaching ₹35.90 crore. While sequential (QoQ) performance showed a decline in both revenue and profit, the nine-month (9M FY26) figures remain strong with a 25% growth in net profit to ₹118.34 crore. The company maintains healthy margins despite a rise in employee benefit expenses.
Key Highlights
Consolidated Revenue from operations increased 16.3% YoY to ₹112.12 crore from ₹96.38 crore.
Net Profit for the quarter rose 29.1% YoY to ₹35.90 crore, up from ₹27.80 crore in Q3 FY25.
9M FY26 total income reached ₹381.51 crore compared to ₹328.25 crore in 9M FY25.
Employee benefit expenses increased to ₹55.13 crore in Q3 FY26 from ₹50.33 crore YoY.
Consolidated Profit Before Tax (PBT) for the quarter stood at ₹48.99 crore.
👀 What to Watch
The strong YoY growth and 9-month performance indicate solid business momentum and improved operational efficiency. Investors should view the sequential dip as seasonal and focus on the company's improving annual profitability and market position.
Saregama Q3 FY26: Music Revenue Grows 29% YoY; Strategic Bhansali Stake Finalized
Saregama India Limited reported operating revenue of INR 260 crores for Q3 FY26, with the core music segment growing 29% year-on-year. The company reported an operating PBT of INR 76.5 crores, though a one-time non-cash charge of INR 7 crores for the new Labour Code reduced reported PBT to INR 69.5 crores. Management finalized a strategic minority investment in Bhansali Productions on January 30, 2026, securing exclusive access to marquee film music at pre-agreed costs. The company is pivoting away from in-house film production to focus on short-format video, artist management, and live events.
Key Highlights
Music segment revenue grew 29% YoY in Q3, with 9-month growth reaching 18% despite the Airtel Wynk exit impact.
Finalized strategic minority investment in Bhansali Productions, ensuring future access to high-profile Hindi film music.
New content spend for FY26 projected at INR 275-300 crores, slightly lower than planned due to release delays of major titles.
Artist management vertical now handles 270+ artists with a combined social media following of over 300 million.
Maintained long-term guidance of 21-23% music revenue growth and 32-33% adjusted EBITDA margins.
👀 What to Watch
Investors should focus on the company's transition toward a more capital-efficient model by winding down in-house films and leveraging the Bhansali partnership. The stock remains a strong play on the increasing monetization of music streaming through paid subscriptions in India.
Saregama India CFO Pankaj Chaturvedi Resigns Effective March 31, 2026
Saregama India Limited has announced the resignation of Mr. Pankaj Chaturvedi from the position of Chief Financial Officer (CFO) and Key Managerial Personnel. The resignation was submitted on February 10, 2026, and will take effect from the close of business hours on March 31, 2026. The company cited personal reasons for his departure and confirmed there are no other material reasons. This transition period gives the company approximately seven weeks to identify and appoint a successor.
Key Highlights
Mr. Pankaj Chaturvedi resigned as CFO and Key Managerial Personnel on February 10, 2026.
The resignation is scheduled to be effective from the close of business hours on March 31, 2026.
Departure is attributed to personal reasons with no other material concerns cited by the outgoing CFO.
The company has a transition window of nearly 50 days to manage the leadership change.
👀 What to Watch
Investors should monitor the company's upcoming announcements regarding the appointment of a new CFO to ensure continuity in financial management. The planned transition period suggests an orderly exit, but the choice of successor will be key for maintaining market confidence.
India Ratings Places Waaree Renewable's INR 258M Bank Facilities on Rating Watch
India Ratings and Research (Ind-Ra) has placed Waaree Renewable Technologies Limited's bank loan facilities worth INR 258 million on 'Rating Watch with Developing Implications'. The facilities, primarily involving the Indian Renewable Energy Development Agency Limited (IREDA), currently hold an 'IND A' rating. This 'Watch' status indicates that the rating could change based on upcoming developments or further information. Investors should note that while the current rating is investment grade, the developing implications suggest a period of uncertainty regarding the credit profile.
Key Highlights
Bank loan facilities totaling INR 258.00 million placed on Rating Watch with Developing Implications.
The current credit rating assigned by India Ratings is 'IND A'.
The primary lender for the rated facilities is the Indian Renewable Energy Development Agency Limited (IREDA).
The rating action was officially communicated to the company on February 05, 2026.
The 'Developing Implications' status suggests potential for rating movement based on future events or data.
👀 What to Watch
Investors should monitor the upcoming detailed credit rating rationale to understand the specific factors causing the 'Developing Implications' status. Maintain a neutral stance until the rating agency provides a final outlook or rating resolution.
Share India to Hold NCLT-Convened Meeting on March 13 for Silverleaf Capital Amalgamation
Share India Securities has scheduled NCLT-convened meetings on March 13, 2026, to seek approval for the amalgamation of Silverleaf Capital Services Private Limited into the company. The meetings will be held via video conferencing for equity shareholders, NCD holders, and creditors. The cut-off date to determine voting eligibility for shareholders and NCD holders is March 6, 2026. This move follows the initial merger disclosure made in September 2025 and represents a significant step in the company's corporate restructuring.
Key Highlights
NCLT-convened meetings scheduled for March 13, 2026, starting at 12:00 PM for equity shareholders.
Remote e-voting period is set from March 9, 2026 (9:00 AM) to March 12, 2026 (5:00 PM).
Cut-off date for determining voting rights for shareholders and NCD holders is March 6, 2026.
The merger involves the transferor company Silverleaf Capital Services Private Limited.
Separate meetings are mandated for Secured Creditors (3:30 PM) and Unsecured Creditors (4:30 PM).
👀 What to Watch
Investors should review the scheme of amalgamation details in the provided notice links to assess the impact on share value. Eligible shareholders should participate in the e-voting process between March 9 and March 12 to exercise their rights.
Waaree Energies Subsidiary Secures 150MW Solar Module Order from International IPP
Waaree Energies' US-based subsidiary, Waaree Solar Americas Inc., has bagged a contract to supply 150MW of solar modules to a major international Independent Power Producer. The supply is scheduled to take place across the years 2026 and 2027, providing healthy revenue visibility for the next two fiscal years. This order strengthens the company's international footprint and market share in the competitive US solar market. The transaction is between non-related parties and was conducted at arm's length.
Key Highlights
Receipt of a 150MW solar module supply order from a renowned international IPP
Order secured through wholly owned subsidiary Waaree Solar Americas Inc.
Supply timeline spans across the calendar years 2026 and 2027
The contract is a one-time international order with no promoter interest involved
👀 What to Watch
Investors should view this as a positive development for the company's export order book and US market penetration. Monitor the execution timeline and its impact on upcoming quarterly revenue realizations.
Hindware Home Innovation Announces NCLT-Directed Meeting for Composite Scheme of Arrangement
Hindware Home Innovation Limited is progressing with a Composite Scheme of Arrangement involving its subsidiaries HHIL Limited and Hindware Limited. As per NCLT Kolkata Bench directions, a meeting of unsecured creditors of Hindware Limited is scheduled for March 7, 2026, to approve the restructuring. The company has already secured no-objection letters from BSE and NSE in August 2025. The cut-off date for determining the entitlement of voting rights for creditors was fixed as September 30, 2025.
Key Highlights
Meeting of unsecured creditors of Hindware Limited scheduled for March 7, 2026, in Kolkata.
Cut-off date for determining voting rights of unsecured creditors set as September 30, 2025.
Scheme involves demerger and merger between Hindware Home Innovation, HHIL Ltd, and Hindware Ltd.
No-objection letters received from BSE and NSE on August 28 and 29, 2025, respectively.
Restructuring is being conducted under Sections 230 to 232 of the Companies Act, 2013.
👀 What to Watch
Investors should monitor the outcome of the creditors' meeting and subsequent NCLT approvals to understand the final corporate structure. Evaluate how the demerger of specific business units might impact the listed entity's valuation.
Hindware Home Innovation to Hold Creditors Meeting on March 7 for Composite Scheme of Arrangement
Hindware Home Innovation Limited (HINDWAREAP) has convened a meeting of unsecured creditors for its subsidiary, Hindware Limited, on March 7, 2026. This meeting is mandated by the NCLT Kolkata Bench to vote on a Composite Scheme of Arrangement involving the parent company, HHIL Limited, and Hindware Limited. The cut-off date for determining voting eligibility was September 30, 2025. Stock exchanges (BSE and NSE) have already issued no-objection letters for the proposed restructuring in August 2025.
Key Highlights
Creditors meeting scheduled for March 7, 2026, following NCLT orders dated December 2025.
Scheme involves a demerger and merger process between Hindware Home Innovation, HHIL Ltd, and Hindware Ltd.
Voting rights for unsecured creditors are determined based on a cut-off date of September 30, 2025.
BSE and NSE provided no-objection letters for the scheme on August 28 and 29, 2025, respectively.
👀 What to Watch
Investors should track the progress of this corporate restructuring as it will likely lead to a reorganization of business segments and impact the long-term valuation of the listed entity.
Religare Enterprises Clarifies on Care Health Insurance Demerger and Listing Rumors
Religare Enterprises Limited has issued a clarification to the stock exchanges regarding a media report suggesting a potential demerger and listing of Care Health Insurance. The company stated that there is currently no pending information or event that requires disclosure under SEBI (LODR) Regulations. While management acknowledges they evaluate strategic growth opportunities on an ongoing basis, they confirmed that the news item has no material impact at this stage. This response effectively denies any immediate or finalized plans for the rumored demerger.
Key Highlights
Exchange sought clarification on a Moneycontrol article dated February 03, 2026, regarding Care Health Insurance.
Company confirms no event currently exists that requires disclosure under SEBI Regulation 30.
Religare states there is no material impact on the company resulting from the news article.
Management maintains they evaluate strategic opportunities for growth and expansion on an ongoing basis.
The response was filed on February 03, 2026, in response to surveillance queries from BSE and NSE.
👀 What to Watch
Investors should treat the demerger news as speculative until an official board-approved announcement is made. Monitor the stock for price volatility as the market reacts to the company's denial of immediate plans.
Saregama Q3 FY26 PAT Rises 17% to Rs 512 Mn; Music Licensing Revenue Up 23% QoQ
Saregama reported a robust Q3 FY26 with revenue from operations reaching Rs 2,604 Mn, a 13% sequential growth. Net profit (PAT) increased by 17% to Rs 512 Mn, even after accounting for a Rs 70 Mn non-cash exceptional charge related to labour code implementation. The company made a significant strategic move by acquiring a minority stake in Bhansali Productions, securing exclusive access to marquee Hindi film music. The core Music Licensing and Artiste Management segment remains the primary growth engine, recording a 29% year-on-year revenue increase.
Key Highlights
Revenue from operations stood at Rs 2,604 Mn, recording a 13% QoQ growth.
Music Licensing and Artiste Management revenue grew by 23% QoQ and 29% YoY.
Operational PBT (excluding exceptional items) grew 27% to Rs 765 Mn.
Strategic investment in Bhansali Productions provides exclusive music IP access at predictable costs.
Digital footprint reached 550 Mn+ followers with YouTube views hitting 278 Bn in Q3.
👀 What to Watch
Investors should focus on the company's aggressive IP acquisition strategy and the high-margin growth in music licensing. The strategic partnership with Sanjay Leela Bhansali acts as a significant moat for future content pipeline.
Saregama Q3 FY26 Revenue up 13% QoQ to Rs 2,604 Mn; Music Licensing grows 29% YoY
Saregama reported a robust Q3 FY26 with revenue reaching Rs 2,604 Mn, driven by a 23% QoQ surge in its core Music Licensing and Artiste Management segment. Operational PBT grew by 27% to Rs 765 Mn, although reported PAT growth was 17% at Rs 512 Mn due to a one-time Rs 70 Mn non-cash charge for labour code implementation. A strategic minority investment in Bhansali Productions was a key highlight, securing exclusive access to marquee Hindi film music. The company continues to scale its digital footprint, now reaching 550 million followers across social platforms.
Key Highlights
Revenue from operations stood at Rs 2,604 Mn, marking a 13% QoQ growth.
Music Licensing and Artiste Management revenue grew 23% QoQ and 29% YoY to Rs 2,038 Mn.
Adjusted EBITDA reached Rs 1,210 Mn, while PAT grew 17% YoY to Rs 512 Mn.
Strategic minority investment in Bhansali Productions ensures exclusive access to future music IPs.
Digital reach expanded to 550 million subscribers with 278 billion YouTube views in the quarter.
👀 What to Watch
Investors should focus on the strong growth in high-margin licensing revenue and the strategic value of the Bhansali partnership. The company's successful diversification into live events and influencer management provides a healthy long-term growth runway.
Saregama Q3 FY26 PAT Rises 17% QoQ to ₹51.2 Cr; Music Segment Shows Steady Growth
Saregama reported a consolidated revenue of ₹260.4 crore for Q3 FY26, marking a 13.2% growth on a sequential basis. Net profit (PAT) stood at ₹51.2 crore, up 16.9% QoQ, although it declined 17.8% compared to the exceptionally high base of the previous year. The core Music segment remains the primary driver, contributing ₹179.7 crore to revenue with healthy margins. The significant YoY decline in total revenue is attributed to the 'Events' segment, which had a massive one-off revenue spike in the same quarter last year.
Key Highlights
Consolidated Revenue from Operations grew 13.2% QoQ to ₹26,038 Lakhs.
Profit After Tax (PAT) increased 16.9% QoQ to ₹5,124 Lakhs.
Music segment revenue grew 12.2% QoQ to ₹17,969 Lakhs, contributing 69% of total revenue.
Artist Management segment saw a sharp 53.7% QoQ jump in revenue to ₹3,979 Lakhs.
An exceptional item of ₹698 Lakhs (expense) impacted the bottom line during the quarter.
👀 What to Watch
Investors should focus on the steady growth and high margins of the core Music segment rather than the volatile Events business. While YoY comparisons look weak due to a high base, the sequential recovery in profitability and growth in Artist Management are positive indicators.
Thyrocare Q3 FY26: Revenue Grows 18% YoY; Pathology Up 20% with Record 10,300 Franchisees
Thyrocare reported a strong Q3 FY26 with consolidated revenue growing 18% YoY, led by a 20% surge in the pathology segment. The company processed 49.6 million tests, a 22% increase, and expanded its active franchisee base to a record 10,300 partners. While the core franchisee business grew 12%, the partnership and insurance segments saw robust growth of 39% and 70% respectively. Management also highlighted achieving Six Sigma quality standards and the appointment of new leadership to drive further expansion.
Key Highlights
Consolidated revenue grew 18% YoY, with the core pathology business increasing by 20%.
Total tests processed rose 22% YoY to 49.6 million, serving 4.5 million patients (up 14% YoY).
Active quarterly franchisee base reached an all-time high of 10,300, up from 9,165 in the previous year.
Partnership business revenue jumped 39% YoY, while the pre-policy medical checkup segment grew 70%.
Achieved Six Sigma quality benchmark with 3.2 complaints per million tests, a 43% YoY improvement.
👀 What to Watch
Investors should monitor the scaling of the partnership business and the path to breakeven for the Tanzania operations. The strong volume growth and record franchisee additions indicate robust market share gains and operational efficiency.
Saregama Completes INR 325 Crore Investment in Bhansali Productions
Saregama India Limited has officially completed the acquisition of securities in Bhansali Productions Private Limited (BPPL). The company has subscribed to 9,960 Compulsory Convertible Preference Shares (CCPS) for a total consideration of INR 325 Crores. This strategic investment, finalized on January 30, 2026, aligns with Saregama's focus on high-quality content and intellectual property. The deal strengthens the company's relationship with one of India's premier film production houses led by Sanjay Leela Bhansali.
Key Highlights
Acquisition of 9,960 Compulsory Convertible Preference Shares (CCPS) completed.
Total investment consideration stands at INR 325 Crores.
The CCPS carry a face value of Rs 10 each with a 0.0001% dividend rate.
Strategic partnership with Sanjay Leela Bhansali's production house to boost content IP.
Transaction concluded following the initial investment agreement dated December 16, 2025.
👀 What to Watch
Investors should monitor the synergy between Saregama's music business and BPPL's film projects, as this could lead to significant IP monetization. The stock remains a long-term play on the Indian media and entertainment sector's growth.
Share India Q3 FY26: Standalone PAT up 35% YoY; ADTO jumps 29% to ₹9,700 Cr
Share India Securities reported a steady Q3 FY26 with consolidated PAT growing 8% YoY to ₹89 crore, while standalone PAT surged 35% to ₹81 crore. The company saw significant operational growth with Average Daily Turnover (ADTO) increasing 29% QoQ to ₹9,700 crore, driven by commodity market volatility. Management is diversifying into wealth management, PMS, and debt markets, with several new subsidiaries expected to be operational by Q1 FY27. A third interim dividend of ₹0.40 per share was also declared.
Key Highlights
Standalone revenue grew 18% YoY to ₹305 crore, with standalone PAT increasing 35% to ₹81 crore
Consolidated ADTO rose by 29% QoQ to ₹9,700 crore, supported by increased interest in commodities
Institutional client base expanded by 13% QoQ to 174 active institutions
Declared a third interim dividend of ₹0.40 per share (20% on face value of ₹2)
MTF book grew 3% QoQ to ₹457 crore despite high market volatility in small and mid-cap segments
👀 What to Watch
Investors should monitor the execution of the new wealth management and AIF verticals launching in FY27, which could diversify revenue streams beyond traditional broking. The strong growth in ADTO and institutional empanelment suggests increasing market share and operational efficiency.
R. S. Software Approves Audited Q2 FY26 Results; Auditors Issue Unmodified Opinion
R. S. Software (India) Limited has officially approved its audited standalone and consolidated financial results for the quarter and half-year ended September 30, 2025. A key takeaway for investors is that the statutory auditors have issued an unmodified opinion, indicating that the financial statements present a true and fair view without any major accounting reservations. The board meeting was conducted on November 05, 2025, and the results were prepared in compliance with Schedule III of the Companies Act 2013. While the specific P&L figures were not detailed in this cover letter, the audited nature of the report adds a layer of reliability to the performance data.
Key Highlights
Board approved audited standalone and consolidated financial results for the period ending September 30, 2025.
Statutory auditors provided an unmodified opinion on the financial reports, ensuring transparency.
The board meeting was held on November 05, 2025, lasting approximately 70 minutes.
The company confirmed compliance with the reporting formats prescribed under the Companies Act 2013.
👀 What to Watch
Investors should examine the detailed financial tables to analyze revenue growth and margin trends for the quarter. The unmodified auditor opinion is a positive sign regarding the company's financial reporting integrity.
Religare Subsidiary Care Health Insurance Rating Upgraded to IND AA-/ Stable
India Ratings & Research (Ind-Ra) has upgraded the credit rating of Care Health Insurance Limited, a material subsidiary of Religare Enterprises. The rating has been moved to 'IND AA-' with a 'Stable' outlook as of January 29, 2026. This upgrade signifies improved financial strength and operational stability for the subsidiary, which is a key value driver for the parent company. Such a rating improvement typically enhances the subsidiary's ability to attract capital and reflects a robust solvency profile.
Key Highlights
Credit rating of material subsidiary Care Health Insurance upgraded to IND AA-.
Rating outlook assigned as 'Stable' by India Ratings & Research (Ind-Ra).
The rating action was communicated on January 29, 2026, and officially disclosed on January 30, 2026.
Care Health Insurance is a significant contributor to the consolidated performance of Religare Enterprises.
👀 What to Watch
Investors should view this upgrade as a positive development for Religare's valuation, as its health insurance arm shows strengthening fundamentals. Maintain a positive outlook on the stock while monitoring the subsidiary's growth in the competitive health insurance market.
Waaree Energies Q3 FY26: Revenue Jumps 119% YoY; EBITDA Guidance Upgraded
Waaree Energies reported a stellar Q3 FY26 with revenue growing 118.8% YoY to ₹7,565 crore and PAT rising 118.4% to ₹1,107 crore. The company achieved record quarterly module production of 3.5 GW and maintains a massive order book of ₹60,000 crore. Management has indicated they will likely surpass their previous FY26 EBITDA guidance of ₹5,500-₹6,000 crore. Strategic expansions into inverters, batteries, and green hydrogen are progressing on schedule for FY27-FY28.
Key Highlights
Revenue grew 118.8% YoY to ₹7,565.05 Cr; EBITDA margins expanded to over 25% in Q3.
Robust order book of ₹60,000 Cr and a pipeline exceeding 100 GW provide strong future visibility.
Cell production utilization reached ~80-81% currently, up from a 56% average during the Q3 period.
Management expects to exceed the FY26 EBITDA guidance range of ₹5,500-₹6,000 Cr.
Diversifying into 'Waaree 2.0' with 20 GWh battery storage and 1 GW electrolyser facilities planned for FY27-FY28.
👀 What to Watch
The company shows exceptional growth and margin expansion, making it a key beneficiary of the solar boom. Investors should hold for long-term gains while monitoring the successful execution of the new integrated energy segments.
Thyrocare Q3 FY26 Results: Consolidated PAT Jumps 47% YoY to ₹27.9 Cr; Revenue Up 18%
Thyrocare Technologies reported a strong performance for Q3 FY26, with consolidated revenue growing 18% YoY to ₹195.5 crore. The company's profitability saw a significant boost as Reported EBITDA rose 38% YoY to ₹57.6 crore and Profit After Tax (PAT) surged 47% to ₹27.9 crore. Operational metrics remained robust with a 22% increase in tests conducted (49.6 million) and a 14% rise in patient volume. While the radiology segment saw a 7% revenue decline due to strategic exits from non-profitable centers, the core pathology business and partnership segments (up 39%) drove overall growth.
Key Highlights
Consolidated Revenue increased 18% YoY to ₹195.53 crore, driven by 20% growth in standalone pathology.
Reported EBITDA grew 38% YoY to ₹57.64 crore, with margins expanding from 25% to 29%.
Net Profit (PAT) surged 47% YoY to ₹27.91 crore; excluding exceptional items, PAT grew 80% to ₹34.07 crore.
Operational volume reached 49.6 million tests (+22% YoY) and 4.5 million patients (+14% YoY).
Partnership revenue grew by 39% YoY, while the active franchisee base expanded by 12% to approximately 10,300.
👀 What to Watch
The company demonstrates strong operational leverage and volume-led growth in its core pathology segment. Investors should maintain a positive outlook given the margin expansion and robust partnership growth, while monitoring the impact of the new brand ambassador on retail market share.
Thyrocare Q3 FY26 Results: PAT Surges 47% YoY to ₹27.91 Cr, Revenue Up 18%
Thyrocare Technologies reported a robust Q3 FY26 with consolidated revenue growing 18% YoY to ₹195.53 crore, primarily driven by a 20% growth in the pathology segment. Profit After Tax (PAT) jumped 47% YoY to ₹27.91 crore, while EBITDA increased by 38% YoY to ₹57.64 crore, reflecting strong operational efficiency. The company processed a record 49.6 million tests, marking a 22% YoY volume growth. Additionally, partnership revenue, including PharmEasy, saw a significant 39% YoY increase, further strengthening its market position.
Key Highlights
Consolidated revenue grew 18% YoY to ₹195.53 crore, led by 20% growth in Pathology.
PAT surged 47% YoY to ₹27.91 crore; EBITDA rose 38% YoY to ₹57.64 crore.
Test volumes increased by 22% YoY to 49.6 million tests processed in Q3.
Partnership revenue (including PharmEasy) recorded robust 39% YoY growth.
Achieved Six Sigma quality standards with complaints reduced to 3.2 per million tests.
👀 What to Watch
Investors should view these results positively as the company demonstrates strong volume growth and margin expansion. The significant growth in partnership revenue and operational benchmarks suggests a sustainable competitive advantage in the diagnostic space.
